文献速递心律失常心力衰竭与心肌病瓣膜病与结构性心脏病

致心律失常性右心室心肌病:诊断与风险分层的重点更新

Arrhythmogenic right ventricular cardiomyopathy: a focused update on diagnosis and risk stratification.
PubMed 文献 · Heart · 2021-05-14

本文综述致心律失常性右心室心肌病(ARVC)的诊断与风险分层现状。诊断方面,2010年标准仍在改进,应变成像、心脏磁共振延迟强化和T1 mapping等指标被建议纳入以提高早期诊断敏感性。风险分层方面,传统专家共识流程图已被两个多变量风险预测模型(arvcrisk.com)补充,但均需临床验证。

要点

  • 应变成像对临床前ARVC诊断敏感性高,可能有助于早期诊断。
  • 心脏磁共振延迟强化和T1 mapping检测的纤维脂肪替代作为诊断标准需更多队列证据。
  • 植入式心律转复除颤器是唯一证实的预防心源性猝死疗法,风险预测模型需验证。

核心结论

  • ARVC诊断标准仍在改进中,应变成像和心脏磁共振纤维脂肪替代检测有望提高早期诊断敏感性。
  • 风险分层已从专家共识流程图发展为两个多变量风险预测模型(arvcrisk.com),但均需临床验证。

研究设计与样本

  • 本文为综述,总结ARVC诊断与风险分层的当前最新进展。

主要发现

  • 应变成像对临床前疾病显示高敏感性,可能促进早期诊断。
  • 心脏磁共振延迟强化或T1 mapping检测的纤维脂肪替代作为诊断标准被越来越多建议,但需更多连续患者队列证据。
  • 传统右室优势型ARVC之外,致心律失常性心肌病(ACM)和致心律失常性左心室心肌病(ALVC)的标准即将出台。
  • younger age、男性、既往(非)持续性室速、晕厥、T波倒置范围、频发早搏和较低双心室射血分数是后续事件的风险因素。
  • 两个多变量风险预测模型(arvcrisk.com)结合上述风险因素估算个体风险。

关键数值与推荐

  • 2010年诊断标准仍在讨论改进。
  • 应变成像对临床前疾病显示高敏感性。
  • 心脏磁共振延迟强化或T1 mapping检测的纤维脂肪替代作为诊断标准需更多连续患者队列证据。
  • 植入式心律转复除颤器是唯一证实的预防心源性猝死疗法。
  • 两个多变量风险预测模型(arvcrisk.com)结合风险因素估算个体风险,但需临床验证。

临床怎么用

  • 考虑使用应变成像辅助早期诊断ARVC。
  • 心脏磁共振延迟强化和T1 mapping可作为诊断参考,但需更多证据。
  • 使用风险预测模型(arvcrisk.com)进行个体化风险分层,但需临床验证。
  • 植入式心律转复除颤器是预防心源性猝死的主要手段。

局限性

  • 心脏磁共振纤维脂肪替代作为诊断标准需更多连续患者队列证据。
  • 风险预测模型和流程图需临床验证研究确定推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy characterised by fibrofatty replacement of predominantly the right ventricle and high risk of ventricular arrhythmias and sudden cardiac death (SCD). Early diagnosis and accurate risk assessment are challenging yet essential for SCD prevention. This manuscript summarises the current state of the art on ARVC diagnosis and risk stratification. Improving the 2010 diagnostic criteria is an ongoing discussion. Several studies suggest that early diagnosis may be facilitated by including deformation imaging ('strain') for objective assessment of wall motion abnormalities, which was shown to have high sensitivity for preclinical disease. Adding fibrofatty replacement detected by late gadolinium enhancement or T1 mapping in cardiac MRI as criterion for diagnosis is increasingly suggested but requires more supporting evidence from consecutive patient cohorts. In addition to the traditional right-dominant ARVC, standard criteria for arrhythmogenic cardiomyopathy (ACM) and arrhythmogenic left ventricular cardiomyopathy (ALVC) are on the horizon. After diagnosis confirmation, the primary management goal is SCD prevention, for which an implantable cardioverter-defibrillator is the only proven therapy. Prior studies determined that younger age, male sex, previous (non-) sustained ventricular tachycardia, syncope, extent of T-wave inversion, frequent premature ectopic beats and lower biventricular ejection fraction are risk factors for subsequent events. Previous implantable cardioverter-defibrillator indication guidelines were however limited to three expert-opinion flow charts stratifying patients in risk groups. Now, two multivariable risk prediction models (arvcrisk.com) combine the abovementioned risk factors to estimate individual risks. Of note, both the flow charts and prediction models require clinical validation studies to determine which should be recommended.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Bosman LP, Te Riele ASJM. Arrhythmogenic right ventricular cardiomyopathy: a focused update on diagnosis and risk stratification. Heart. 2021. PMID: 33990412. doi:10.1136/heartjnl-2021-319113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。